JNJ Chart

1 Month

	Date	Diff
	2025-02-12	-0.56 %
Johnson & Johnson's (JNJ) stock decreased by 0.56% to $155.27, despite a recent 7.24% gain over the past month, likely due to concerns about its long-term performance despite short-term gains. Johnson & Johnson (JNJ) stock experienced a decline of 0.56% due to a combination of market volatility in the biotechnology sector, uncertainties surrounding corporate acquisitions, and general economic factors following a recent drop in federal interest rates that did not generate the expected surge in investment activity. Johnson & Johnson (JNJ) stock recently declined by 0.56%, likely due to investor concerns reflected in the recent 13F filing by Tweedy Browne, which revealed a significant reduction in their holdings of JNJ as part of broader portfolio adjustments, suggesting a lack of confidence in its future performance.
	2025-02-11	+1.23 %
Johnson & Johnson (JNJ) stock rose by 1.23% last night due to strong financial results and growth prospects reported by Royalty Pharma plc, which highlighted a successful year in royalty receipts and a new $3 billion share repurchase program, reflecting confidence in their business and enhancing shareholder value.
	2025-02-07	-0.25 %
Johnson & Johnson (JNJ) stock recently fell by 0.25%, influenced by mixed analyst ratings, with some firms lowering their price targets, signaling potential concerns about the stock's future performance. Johnson & Johnson (JNJ) stock experienced a 0.25% decline, attributed to concerns over the financial implications of Omnicom's acquisition of IPG and the potential loss of significant clients, including JNJ, which raises doubts about IPG's future revenue and stability. Johnson & Johnson (JNJ) stock declined by 0.25% following a series of downgrades in target prices from several analysts, reflecting a cautious outlook for the company despite reporting better-than-expected earnings for the last quarter. Johnson & Johnson (JNJ) stock recently declined by 0.25%, influenced by a reduction in positions by major investors and analysts lowering their price targets for the stock. Johnson & Johnson (JNJ) stock experienced a decline of 0.25% following Optas LLC's disclosure of a 15.6% reduction in its holdings, amidst other institutional adjustments in stock positions. The stock decrease may reflect market sensitivity to hedge fund movements and changes in ownership structures, leading to investor uncertainty.
	2025-02-06	-0.76 %
Johnson & Johnson (JNJ) stock declined by 0.76% due to concerns that a stronger US dollar, influenced by President Trump's tariff plans, is negatively impacting the company's overseas revenue, as they reported a $1.7 billion adverse effect on 2024 sales from unfavorable foreign currency moves.
	2025-02-05	+0.78 %
Johnson & Johnson (JNJ) stock rose by 0.78% due to a mix of institutional investors adjusting their holdings positively and strong quarterly earnings results that exceeded analysts' expectations, indicating robust business performance. Johnson & Johnson (JNJ) stock rose 0.78% due to positive institutional investment activity, including increased stakes and recent insider purchases, along with strong quarterly earnings that surpassed expectations. Johnson & Johnson's stock (JNJ) rose by 0.78% after SeaBridge Investment Advisors LLC and other institutional investors increased their stakes in the company, reflecting growing investor confidence and a positive earnings report that exceeded analysts' expectations. Johnson & Johnson (JNJ) stock rose by 0.78% following reports of increased institutional investment and a positive quarterly earnings report, which included earnings surpassing expectations and revenue growth, coupled with a proposed dividend increase. Johnson & Johnson (JNJ) stock rose by 0.78% due to institutional investors increasing their stakes in the company, positive earnings reports exceeding analyst expectations, and recent upgrades from equity analysts.
	2025-02-04	+1.07 %
Johnson & Johnson (JNJ) stock rose by 1.07% partly due to positive quarterly earnings results, where the company reported higher-than-expected earnings and revenue, along with supportive actions from institutional investors and analysts raising price targets for the stock. Johnson & Johnson (JNJ) stock increased by 1.07% as institutional investors and hedge funds have significantly raised their stakes in the company, reflecting positive investor sentiment and confidence in its performance. Johnson & Johnson's (JNJ) stock rose by 1.07% likely due to significant institutional investment increases, positive quarterly earnings performance that exceeded expectations, and the announcement of a forthcoming dividend, all contributing to investor confidence in the company. Johnson & Johnson (JNJ) stock rose 1.07% due to positive institutional investor activities, strong quarterly earnings surpassing expectations, and an upcoming dividend payment, which collectively enhanced investor confidence. Johnson & Johnson (JNJ) stock rose by 1.07% due to positive investor sentiment, which could be influenced by strong institutional ownership and favorable analyst recommendations for its focus on innovative medical solutions.
	2025-02-03	-0.18 %
The article discusses the confirmation hearings for Robert F. Kennedy Jr. as HHS Secretary, highlighting the significant influence of the pharmaceutical industry on lawmakers, particularly those who criticize Kennedy while having received substantial donations from Big Pharma, which raises questions about their commitment to public health—this negative sentiment surrounding the hearings may contribute to the decline in Johnson & Johnson (JNJ) stock. Johnson & Johnson's stock may have gone down due to increased scrutiny and criticism of the pharmaceutical industry, potentially reflecting concerns about accountability, regulation, and public health priorities that can impact investor confidence. Johnson & Johnson (NYSE:JNJ) stock experienced a slight decline of -0.18%, attributed to increased competition and investment interest in oncology and AI stocks which are viewed as having greater growth potential than JNJ's current offerings.
	2025-01-31	-0.47 %
Johnson & Johnson (JNJ) stock declined by 0.47% due to a broader market trend influenced by perceptions shaped by specialty public relations, which significantly impact investor sentiment and market behavior. Johnson & Johnson (JNJ) stock fell by 0.47% due to broader market trends and investor concerns that may have overshadowed the company's performance. Johnson & Johnson's (JNJ) stock fell by 0.47% despite a recent upgrade in price target by Barclays due to concerns over large investor activity and mixed analyst ratings affecting market sentiment. The decline in JNJ's stock may be attributed to various factors including shifts in analyst price targets, a decrease in trading volume, and the overall market reaction to recent earnings results compared to previous performance.
	2025-01-30	+1.14 %
Johnson & Johnson (JNJ) stock rose by 1.14% due to a combination of positive quarterly earnings exceeding analyst expectations, modest increases in revenues, ongoing institutional investment activity, and favorable ratings from research analysts. Johnson & Johnson (JNJ) stock rose by 1.14% following positive quarterly earnings results that exceeded analyst expectations and the declaration of a quarterly dividend, indicating strong financial performance and ongoing confidence among investors. Johnson & Johnson (JNJ) stock rose by 1.14% following positive quarterly earnings results that exceeded consensus estimates, along with recommendations from analysts that boosted market confidence in the company's future performance. Johnson & Johnson's (NYSE: JNJ) stock rose 1.14% following an increase in its price target by Barclays from $159.00 to $166.00, coupled with positive quarterly earnings results that exceeded analyst expectations. The Johnson & Johnson (JNJ) stock rose 1.14% due to a positive earnings report that exceeded analysts' expectations, coupled with changes in institutional investors' holdings and an upgrade by some analysts to a "strong-buy" rating.
	2025-01-29	+0.51 %
Johnson & Johnson (JNJ) stock rose by 0.51% amid ongoing controversies involving pharmaceutical interests and the nomination of Robert F. Kennedy Jr. for a health position, which some perceive as a challenge to established Big Pharma policies and interests that may indirectly affect JNJ’s market performance.
	2025-01-28	-1.64 %
Johnson & Johnson (JNJ) stock fell 1.64% attributed to concerns over its drug discovery collaborations and the competitive landscape posed by innovative firms like Xtalpi, which is leveraging AI and quantum physics for faster and potentially more cost-effective drug development. The article reports that Johnson & Johnson (JNJ) stock fell by 1.64% following a purchase filed by Representative Marjorie Taylor Greene valued between $3,003 and $45,000. The decline in Johnson & Johnson's stock could be attributed to market reactions to the news of the purchase or broader market trends, but specific reasons for the decrease are not detailed in the provided text.
	2025-01-27	+4.13 %
Johnson & Johnson's stock (JNJ) rose 4.13% due to positive earnings results that exceeded estimates, a new stake purchase by MFA Wealth Services, and overall supportive activity from institutional investors in the fourth quarter. Johnson & Johnson (JNJ) stock rose 4.13% due to increased institutional investments and a positive earnings report, where it exceeded analysts' expectations for earnings per share and revenue growth. Johnson & Johnson (JNJ) stock increased by 4.13% following a strong earnings report that exceeded analysts' expectations, alongside significant investment activity from institutional investors and positive analyst ratings. Johnson & Johnson (JNJ) stock rose by 4.13% following an upgrade from a "buy" to a "strong-buy" rating by StockNews.com, along with positive reactions from various analysts and better-than-expected quarterly earnings results that exceeded analyst estimates. Johnson & Johnson's stock (JNJ) rose by 4.13% following positive quarterly earnings results that exceeded analyst expectations, along with continued strong institutional investment interest in the company.
	2025-01-24	+0.12 %
Johnson & Johnson (JNJ) stock rose 0.12% after the company reported better-than-expected Q4 results, with revenues of $22.5 billion and adjusted earnings of $2.04 per share, and provided an optimistic sales outlook for 2025, despite facing some challenges from biosimilar competition for one of its top-selling drugs.
	2025-01-23	+0.94 %
Johnson & Johnson's (JNJ) stock increased by 0.94% following unusual options trading activity and a positive quarterly earnings report that exceeded analysts' expectations, along with solid revenue growth year-over-year. Johnson & Johnson's stock (JNJ) increased by 0.94% following a quarterly earnings report that exceeded analysts' expectations, showcasing a revenue rise, which indicates strong performance and future growth potential despite some recent price target adjustments by analysts.
	2025-01-22	-1.94 %
Johnson & Johnson (JNJ) stock fell by 1.94% due to a combination of institutional investor movements, recent downgrades in target prices from several research analysts, and overall market conditions. Johnson & Johnson's stock (JNJ) fell by 1.94% following the FDA's approval of their nasal spray, Spravato, for treating major depressive disorder, which may have sparked concerns about competition in the market for depression treatments. Johnson & Johnson (JNJ) stock fell by 1.94%, influenced by recent analyst downgrades in price targets, reflecting a broader sentiment shift among investors, despite steady institutional investment growth and upcoming dividend announcements. Johnson & Johnson (JNJ) stock fell by 1.94% primarily due to analyst downgrades and shifts in institutional investor positions, as indicated by reduced ratings and targeted price cuts from various brokerages. Johnson & Johnson's (JNJ) stock fell by 1.94% despite positive fourth-quarter and full-year 2024 results due to concerns over ongoing legal issues related to talc products, potential negative impacts from foreign exchange and slower medical device sales, as well as competitive pressures from generics and pricing negotiations with Medicare.
	2025-01-21	+0.76 %
Johnson & Johnson (JNJ) stock rose by 0.76% following significant institutional investments, including a new position by Whitaker Myers Wealth Managers and increased stakes from several other hedge funds, along with positive analyst ratings and a commitment to a healthy dividend. Johnson & Johnson (JNJ) stock rose 0.76% ahead of its upcoming fourth-quarter earnings report, which is anticipated to show $2 in EPS and $22.44 billion in revenues, contributing to positive investor sentiment despite a 8.88% decline over the past year. The stock's rise may be attributed to expectations of positive earnings results and positive developments such as the approval of Spravato. Johnson & Johnson's stock increased by 0.76% as several institutional investors have recently adjusted their stakes in the company, alongside positive price target upgrades from various research firms, indicating strong market confidence in JNJ's long-term prospects. Johnson & Johnson (NYSE: JNJ) shares increased by 0.76% as institutional investors, including Smith Salley Wealth Management, made significant adjustments to their holdings, and positive analyst ratings lifted market sentiment. The stock's rise can be attributed to strong institutional buying activity and favorable analyst upgrades, indicating confidence in the company's financial performance and future growth prospects. Johnson & Johnson's stock rose 0.76% following the announcement of its merger agreement with Intra-Cellular Therapies, which involves acquiring the company for $132.00 per share in cash, reflecting investor optimism about potential growth and strategic benefits from the merger.
	2025-01-17	-0.5 %
Johnson & Johnson's stock (JNJ) dropped by 0.5% following a downgrade from a "strong-buy" rating to a "buy" rating by analysts at StockNews.com, despite positive earnings results that exceeded analysts' expectations. Johnson & Johnson (JNJ) stock, which was down 0.5%, is likely influenced by the broader market dynamics where a tech stock revival and positive earnings reports have shifted investor sentiment, while uncertainty surrounding upcoming policy changes under the Trump administration may have also contributed to JNJ's decline amid increased competition and regulatory pressures in the healthcare sector. Johnson & Johnson (JNJ) stock decreased by 0.5% amid a generally positive market environment where major indices surged after favorable CPI inflation data, which raised expectations for interest rate cuts by the Federal Reserve. The decline in JNJ's stock may be attributed to a broader focus on upcoming earnings reports and potential investor sentiment shifting towards other sectors that are performing well, particularly major banks. Johnson & Johnson (JNJ) stock fell by 0.5% due to ongoing concerns over lawsuits related to its talc products, alongside uncertainty surrounding broader market conditions influenced by upcoming political changes and earnings reports from other companies. Johnson & Johnson (JNJ) stock fell by 0.5% due to various market factors, including possible investor reaction to recent trades and broader market trends, although the article did not specifically elaborate on the reasons for the decline.
	2025-01-16	+1.93 %
The article discusses the ownership dynamics of NFL teams and the varying degrees of success associated with each owner, while highlighting that Johnson & Johnson (JNJ) stock rose by 1.93% last night, likely due to positive investor sentiment influenced by factors such as strong financial performance or strategic business developments.
	2025-01-15	+0.15 %
Johnson & Johnson (JNJ) stock rose by 0.15% due to strong institutional ownership and favorable analyst ratings, indicating market confidence in the company's long-term performance compared to competitors like RegeneRx Biopharmaceuticals. Johnson & Johnson (JNJ) stock rose by 0.15% due to a combination of analysts' positive target price adjustments and recent insider buying, alongside the company's strong quarterly earnings performance that exceeded expectations. Johnson & Johnson (JNJ) stock increased by 0.15% as part of a broader market trend where investors remain optimistic about healthcare stocks, despite mixed news surrounding competitors like Eli Lilly. The rise in JNJ stock may be attributed to positive sentiment in the healthcare sector and investors looking for stable investment opportunities.
	2025-01-14	+0.19 %
Johnson & Johnson (JNJ) stock rose 0.19% due to its acquisition of Intra-Cellular Therapies, Inc. for $132.00 per share in cash, which may have positively influenced investor sentiment regarding JNJ's growth prospects. Johnson & Johnson (JNJ) stock rose 0.19% last night, likely due to positive sentiments stemming from recent analyst upgrades and favorable performance indicators in the broader market context. Johnson & Johnson (JNJ) stock rose 0.19% recently, driven by increased investor confidence stemming from discussions of a potential $10 billion acquisition of Intra-Cellular Therapies Inc. (ITCI) following ITCI's successful sales of the antipsychotic drug Caplyta and its recent legal victory over Sandoz. Johnson & Johnson (JNJ) stock rose by 0.19% following the announcement that the company will acquire Intra-Cellular Therapies for $132 per share, which contributed to investor optimism in JNJ's future growth prospects. Johnson & Johnson (JNJ) stock rose 0.19% amid optimism surrounding recent acquisitions and potential regulatory changes under the new Trump administration, which may create a more favorable environment for the pharmaceutical industry compared to the uncertainty caused by the previous Inflation Reduction Act.
	2025-01-13	+1.7 %
Johnson & Johnson's stock (JNJ) rose by 1.7% after the company announced its acquisition of Intra-Cellular Therapies for approximately $14.6 billion, which includes the FDA-approved drug CAPLYTA® and a promising pipeline of treatments for neuropsychiatric disorders, positioning JNJ for significant sales growth in the coming years. Johnson & Johnson (JNJ) stock rose by 1.7% recently due to increased institutional investment, including a notable 6.5% increase in holdings by the Czech National Bank, alongside strong quarterly earnings that exceeded analysts' expectations. Johnson & Johnson's stock rose 1.7% following their announcement of a $14.6 billion acquisition of Intra-Cellular Therapies, which is expected to enhance their portfolio in treating central nervous system disorders. The increase in JNJ's stock is attributed to investor confidence in the growth potential of Intra-Cellular's drug Caplyta and its promising pipeline. Johnson & Johnson's stock rose 1.7% following the announcement of its acquisition of Intra-Cellular for over $14 billion, which aims to enhance its neurological drug division and expand into treating central nervous system disorders. Johnson & Johnson's stock rose 1.7% following its announcement to acquire Intra-Cellular Therapies for over $14 billion, which reflects a strategic move to enhance its portfolio in treating central nervous system disorders and capitalize on the growing market potential of Intra-Cellular's drug Caplyta.
	2025-01-10	-0.15 %
The article discusses Royalty Pharma plc's announcement of a transaction aimed at enhancing shareholder value, including a significant share repurchase program and internalization of management, while noting that Johnson & Johnson's stock (JNJ) declined by 0.15%. Johnson & Johnson's stock may have gone down due to general market trends or specific investor reactions to broader economic conditions impacting the biopharmaceutical sector, although the article does not provide detailed reasons for JNJ's decline. Johnson & Johnson (JNJ) stock fell by 0.15% amid underperformance in 2024 due to declining sales from Covid-19 vaccines and its drug Remicade, alongside increasing competition for key products. The article discusses a minor decline of 0.15% in Johnson & Johnson's stock, which can be attributed to broader market movements and recent insider trading activities rather than specific issues with the company's fundamentals. Johnson & Johnson's stock (JNJ) decreased by 0.15% following a downgrade in earnings per share estimates for Q2 2025 by Zacks Research, which raised concerns about the company's future financial performance. Johnson & Johnson (JNJ) stock experienced a 0.15% decline after Representative Lloyd Doggett's recent share purchase and a mixed response from analysts regarding future price targets and ratings, despite the company's reported earnings surpassing analyst expectations. The stock may be affected by ongoing market fluctuations and investor sentiment.
	2025-01-08	-2.71 %
Johnson & Johnson (JNJ) stock fell by 2.71% due to market uncertainties and negative investor sentiment surrounding its growth prospects and earnings outlook. Johnson & Johnson (JNJ) stock fell by 2.71% due to a general decline in healthcare stocks, as the broader market reacted to the Federal Reserve's recent meeting and signals suggesting a potential slowdown in rate easings, which impacted investor sentiment.
	2025-01-07	+1.79 %
Johnson & Johnson (JNJ) stock rose by 1.79% last night, which could be attributed to positive market sentiment or rumors regarding potential developments in the company, as the article primarily discusses leadership changes at XWELL, Inc. and does not provide specific details about JNJ's performance.
	2025-01-06	-0.37 %
The article discusses the stock performance of Johnson & Johnson (JNJ), which fell by 0.37%, highlighting that the company had lower revenue compared to its competitor Materialise, with analysts favoring the latter due to its stronger consensus rating and higher potential upside. JNJ stock may have declined due to negative market sentiment or concerns over its financial performance relative to other tech companies. Johnson & Johnson (NYSE: JNJ) stock declined by 0.37% due to an overall shift in investor focus towards high-quality dividend stocks, amidst concerns over valuation and demand in the AI sector. Johnson & Johnson (JNJ) stock declined by 0.37% as it faced downward pressure despite increased institutional holdings and analysts mostly maintaining positive outlooks, likely due to broader market trends or investor sentiment rather than company-specific issues. Johnson & Johnson (NYSE:JNJ) stock fell by 0.37% due to a notable reduction in its holdings by Burkett Financial Services LLC and fluctuations in investor sentiment, as several institutional investors made significant adjustments to their positions. Johnson & Johnson (JNJ) stock saw a decrease of 0.37% amid mixed analyst ratings and strategic investment movements by large institutional investors, with overall market sentiment likely influencing the decline.
	2025-01-03	+0.12 %
Johnson & Johnson (JNJ) stock rose by 0.12% due to recent FDA approvals of various drugs in regenerative medicine and treatments for rare diseases, which indicate a positive outlook for the healthcare sector and potentially beneficial developments for JNJ's market position. Johnson & Johnson (NYSE:JNJ) stock rose by 0.12% last night, largely influenced by increased institutional investment and favorable analyst ratings, including target price increases from several firms. Johnson & Johnson (JNJ) stock rose by 0.12% likely due to a mix of large investors adjusting their positions and positive analyst ratings, as well as strong quarterly earnings that surpassed expectations, highlighting the company's solid performance in the healthcare sector.
	2025-01-02	-0.41 %
Johnson & Johnson (JNJ) stock decreased by 0.41% primarily due to market reactions after analysts adjusted their price targets, reflecting mixed sentiments despite strong earnings and a consistent dividend history. Shares of Johnson & Johnson (JNJ) experienced a slight decline of 0.41% after trading activity showed significantly lower volume and despite positive analyst comments regarding its stock ratings and price targets. The decline in JNJ stock could be attributed to the overall trading environment and reduced investor interest, as indicated by the sharp drop in trading volume compared to its average. Johnson & Johnson (JNJ) stock recently declined by 0.41%, despite a decrease in short interest and positive analyst ratings, primarily due to market fluctuations and overall investor sentiment.
	2024-12-31	+0.89 %
Johnson & Johnson's stock (NYSE: JNJ) increased by 0.89% after Representative Marjorie Taylor Greene disclosed her recent purchase of shares, alongside positive earnings results that exceeded analysts' expectations, contributing to investor confidence. The stock's rise can be attributed to Greene's investment and strong quarterly earnings performance, which surpassed consensus estimates for both earnings per share and revenue. Johnson & Johnson (JNJ) stock rose by 0.89% due to positive sentiment surrounding biotechnology investments, particularly in Rallybio Co., which has recently received strong analyst ratings and institutional investments, suggesting a strong outlook in the sector.
	2024-12-30	-1.18 %
Johnson & Johnson's (JNJ) stock declined by 1.4% amid low trading volume, potentially influenced by mixed analyst ratings and a broader market environment. The stock's decline could be attributed to reduced investor confidence indicated by the significant drop in trading volume, combined with varying analyst opinions, despite the company’s positive earnings and revenue growth reported in its latest quarterly results. Johnson & Johnson (JNJ) stock declined by 1.18% due to market fluctuations and possibly investor reactions to recent institutional buying activity, as evidenced by varying positions taken by multiple institutional investors and analysts adjusting their price targets and ratings.
	2024-12-27	-0.36 %
Johnson & Johnson (JNJ) stock declined by 0.36% as it entered a bearish technical pattern known as the Death Cross, indicating potential further declines due to the 50-day moving average dropping below the 200-day moving average. Johnson & Johnson (JNJ) stock declined by 0.36% due to ongoing concerns related to its settlement offer aimed at resolving thousands of lawsuits over its talcum powder products linked to ovarian cancer, as the company moved to finalize a $9 billion settlement through a pre-packaged bankruptcy process for its Red River Talc unit.
	2024-12-23	+0.55 %
Johnson & Johnson (JNJ) stock rose by 0.55% due to positive market sentiment and an overall sense of normalcy returning to the economy, despite the company's recent financial reporting issues and fines related to price hikes on their products.
	2024-12-20	+0.62 %
Johnson & Johnson (JNJ) stock rose by 0.62% due to the positive sentiment surrounding Clearside Biomedical, which received multiple "buy" ratings from analysts, indicating strong market confidence in the company's future performance.
	2024-12-17	+1.78 %
Johnson & Johnson (JNJ) stock rose 1.78%, likely as a result of its relative stability amidst significant declines in the health insurance sector, particularly due to the recent turmoil surrounding UnitedHealth Group, which has caused a broader negative sentiment in the market. Johnson & Johnson (JNJ) stock rose by 1.78% despite the Dow Jones Industrial Average experiencing its worst losing streak in nearly 50 years, mainly due to a broader sell-off in healthcare stocks impacting the Dow, but JNJ managed to rebound while other stocks struggled. JNJ's stock may have gone up as it benefited from some investors seeking value amidst the overall decline in the healthcare sector, indicating a potentially positive sentiment or correction following previous losses. Johnson & Johnson (JNJ) stock rose 1.8% amid a generally declining market due to strong performance and forecasts from other healthcare companies, particularly Pfizer, which helped buoy investor confidence in the sector.
	2024-12-16	-1.89 %
Johnson & Johnson (JNJ) stock dropped by 1.89% due to market reactions surrounding significant industry news, specifically Omnicom's proposed $30 billion acquisition of Interpublic Group, which has raised concerns about potential disruptions and uncertainties among clients and shareholders within the advertising sector.
	2024-12-09	+0.19 %
Johnson & Johnson (JNJ) stock rose 0.19% last night, likely benefiting from its strong position in the Drucker Institute's Management Top 250 ranking, where it was recognized as the sixth best-run company in America, alongside other high-performing companies that emphasize corporate effectiveness.
	2024-12-06	-0.14 %
Johnson & Johnson (JNJ) stock fell by 0.14% mainly due to its recent oversold condition, indicated by an RSI of 29.0, suggesting heavy selling pressure that may present a buying opportunity for dividend investors. Johnson & Johnson (JNJ) stock was down by 0.14% likely due to market fluctuations, investor sentiment, or external economic factors affecting healthcare stocks, as the article primarily discusses Rallybio's ratings and performance rather than focusing on JNJ directly.
	2024-12-05	-0.63 %
Johnson & Johnson (JNJ) stock experienced a decline of 0.63% due to overall market volatility and likely investor sentiment weighing on the healthcare sector despite the company's strong fundamentals and innovative growth strategies.
	2024-12-03	-1.58 %
Johnson & Johnson (JNJ) stock was down 1.58% last night, likely due to broader market trends, investor sentiment shifts, or company-specific news impacting its share price, although the article primarily discusses Clearside Biomedical, Inc. and does not directly provide reasons for JNJ's decline.
	2024-12-02	-0.14 %
The article discusses a comparison between two small-cap technology companies, Materialise and MeridianLink, while noting that Johnson & Johnson (JNJ) stock decreased by 0.14% last night, although it does not provide specific reasons for this decline. The drop in Johnson & Johnson's stock price could be due to a variety of factors, such as broader market trends, company-specific news, or investor sentiment, but the article does not specify the cause. Johnson & Johnson (JNJ) stock fell by 0.14% after Dynamic Technology Lab Private Ltd drastically reduced its holdings in the company by 79.5%, impacting market sentiment.
	2024-11-29	-0.25 %
Johnson & Johnson (JNJ) stock declined by 0.25%, likely due to market reactions to the impending end of the lock-up period for Rapport Therapeutics, which may lead to increased selling pressure from insiders and institutional investors.
	2024-11-27	+0.57 %
Johnson & Johnson (JNJ) stock increased by 0.57% due to its strong revenue growth in both pharmaceuticals and medical devices, driven by successful drugs like Darzalex and Stelara, despite facing challenges with older drugs and upcoming loss of exclusivity for Stelara.
	2024-11-22	-0.21 %
The article discusses recent performance insights of Johnson & Johnson (JNJ) stock, which dropped by 0.21%, but primarily focuses on Clearside Biomedical (CLSD), which received a "Buy" rating from analysts and saw significant insider investment. The decline in JNJ stock might be linked to broader market conditions or specific company news, although the article does not provide direct reasons for the drop. Johnson & Johnson (JNJ) stock fell by 0.21% amidst concerns related to a UK class action lawsuit alleging that nearly 2,000 women claim the company's talcum powder products contained asbestos, potentially causing cancer. The stock decline is attributed to the resurgence of legal actions and public scrutiny surrounding the safety of J&J's talc-based products following claims that they may have contained asbestos fibres linked to serious health risks, such as incurable cancer.
	2024-11-21	+1.56 %
Johnson & Johnson (JNJ) stock rose by 1.56% last night, driven by strong revenue growth in its pharmaceuticals and medical devices segments, particularly from treatments for multiple myeloma and autoimmune diseases, despite facing challenges from older drugs losing market exclusivity. Johnson & Johnson (JNJ) stock rose 1.56% last night, likely due to positive investor sentiment and expectations of robust performance in the healthcare sector as potential policy shifts under the Trump administration may favor merger and acquisition activity. Additionally, the article highlights Howard Lutnick, the CEO of Cantor Fitzgerald, who has been nominated by Trump to be commerce secretary, and examines his controversial reputation on Wall Street amid discussions of potential conflicts of interest in his financial dealings.
	2024-11-20	+0.07 %
Johnson & Johnson (JNJ) stock rose by 0.07% likely due to investor confidence influenced by Dr. Mehmet Oz's nomination to lead the Centers for Medicare & Medicaid Services, as his significant investments in healthcare companies, including JNJ, could foster favorable decisions for the healthcare sector.
	2024-11-19	-1.14 %
Johnson & Johnson (JNJ) stock fell by 1.14%, likely due to broader market trends or specific company-related factors that impacted investor sentiment. The article discusses the recent downturn of Johnson & Johnson (JNJ) stock, which fell by 1.14%, but does not provide specific reasons for this decline as it mainly focuses on Clearside Biomedical's stock performance and ratings. Johnson & Johnson (JNJ) stock fell by 1.14% following mixed analyst ratings and changes in price targets amid concerns about its recent earnings performance and market dynamics.
	2024-11-18	+0.5 %
Johnson & Johnson (JNJ) stock increased by 0.5% likely due to positive developments in the myopia treatment sector, particularly following the FDA approval of its ACUVUE Ability Overnight Therapeutic Lenses, contrasting with the failure of Eyenovia's CHAPERONE study that negatively impacted its competitor's stock. The article discusses recent activity and analyst ratings for Clearside Biomedical (CLSD), noting that Johnson & Johnson (JNJ) has invested in the company, which may have contributed to a positive sentiment around its stock performance. The stock price increases are attributed to positive earnings reports exceeding analysts' expectations and increased insider buy-ins, indicating optimism about the company's future.
	2024-11-14	-0.89 %
The article discusses a viral Reddit post featuring a boy's unconventional use of duct tape, which has sparked both amusement and disbelief among users. Johnson & Johnson's (JNJ) stock fell by 0.89% possibly due to broader market trends, company-specific news, or concerns among investors, but the article does not provide specific details on the reasons for the decline.
	2024-11-13	+0.39 %
The article discusses the recent rise in Johnson & Johnson's (JNJ) stock, which was reported to be up by 0.39%, and highlights the positive ratings and institutional investment in Rallybio Co. (RLYB), without directly explaining JNJ's stock increase. The increase in JNJ's stock may be attributed to strong institutional buying and the company's continued investment in biotechnology projects, indicating confidence in future growth potential. Johnson & Johnson (JNJ) stock rose by 0.39% recently, likely due to positive investor sentiment and continued interest in its strong long-term growth potential, as demonstrated by its inclusion in significant investment portfolios like ETFs and its historical portfolio performance.
	2024-11-01	+0.17 %
Johnson & Johnson's stock (JNJ) rose 0.17% likely due to increased institutional investment, particularly a 16.4% growth in holdings by First Trust Direct Indexing L.P., along with positive quarterly earnings that exceeded analysts' expectations and an optimistic outlook from multiple research firms. Johnson & Johnson (JNJ) stock rose by 0.17% recently after positive earnings results exceeded analysts' expectations, boosted by strong revenue growth and favorable analyst ratings increases. Johnson & Johnson (NYSE: JNJ) stock rose by 0.17% following reports of strong quarterly earnings that exceeded analyst expectations, coupled with positive ratings and investment interest from various hedge funds. Johnson & Johnson (JNJ) stock saw a slight increase of 0.17% following positive recommendations from analysts, with a consensus rating of "Moderate Buy" and better-than-expected quarterly earnings that surpassed estimates by $0.21. The stock rose due to favorable earnings results, an increase in revenue, and supportive analyst ratings that suggested a positive outlook for the company's stock. Johnson & Johnson (JNJ) stock saw a slight increase of 0.17%, driven by overall market optimism and investor interest in the company's stable performance within the healthcare sector, which typically remains resilient even in fluctuating economic conditions.
	2024-10-31	-0.47 %
Johnson & Johnson (NYSE: JNJ) stock fell by 0.47% due to a reduction in holdings by Abich Financial Wealth Management LLC and mixed ratings from analysts following changes in their price targets and recommendations for the stock. Johnson & Johnson (NYSE: JNJ) stock fell by 0.47% amid recent portfolio adjustments by institutional investors and hedge funds, including a 3.1% reduction in holdings by Diversify Advisory Services LLC and mixed ratings from analysts regarding the stock's future price expectations. The decline in JNJ stock can be attributed to a combination of institutional investment adjustments and analysts reducing price targets, reflecting market uncertainty about the stock's performance. Johnson & Johnson (JNJ) stock experienced a decline of 0.47% due to recent analyst downgrades and changes in target prices amidst mixed earnings results, despite beating some consensus estimates. Johnson & Johnson (JNJ) stock fell by 0.47% primarily due to institutional investors modifying their positions, including a recent decrease by Tyche Wealth Partners LLC, along with mixed analyst ratings reflecting cautious sentiment.
	2024-10-30	+0.32 %
Johnson & Johnson (JNJ) stock rose by 0.32% due to its strong fundamentals, including higher revenue and earnings compared to competitors, as well as significant institutional ownership, which indicates investor confidence in the company's long-term performance. Johnson & Johnson (JNJ) stock rose by 0.32% due to a combination of positive earnings results that exceeded estimates, strong quarterly revenue growth, and favorable analyst ratings that contribute to a bullish sentiment among institutional investors. Johnson & Johnson (JNJ) stock increased by 0.32% likely due to positive analyst ratings and earnings results, including a reported earnings per share that surpassed estimates and a solid quarterly revenue reflecting year-over-year growth. Johnson & Johnson (JNJ) stock rose by 0.32% due to increased investor confidence following positive quarterly earnings results that exceeded expectations, along with favorable adjustments to target prices by multiple analysts. Johnson & Johnson (JNJ) stock rose by 0.32% due to increased institutional investment, positive quarterly earnings that exceeded expectations, and a generally favorable outlook from analysts regarding its performance and future price targets.
	2024-10-29	-0.93 %
Johnson & Johnson (JNJ) stock fell by 0.93% after several analyst downgrades and adjusted price targets, including a reduction by Goldman Sachs and cuts from a "strong-buy" to a "hold" rating by other brokerages, which contributed to the negative sentiment around the stock. Johnson & Johnson (JNJ) stock dipped 0.93% after the company recently reported earnings that exceeded expectations, amid a backdrop of shifting institutional investments and analysts adjusting price targets and ratings. The stock decline could be attributed to profit-taking or adjustments in investor sentiment following the earnings report, coupled with analysts lowering price targets, suggesting a more cautious outlook for the stock despite its solid quarterly performance. Johnson & Johnson (NYSE: JNJ) stock fell by 0.93% due to various institutional investors adjusting their holdings, with Salomon & Ludwin LLC significantly reducing its stake by nearly 40%, indicating possible negative sentiment or profit-taking among large shareholders. Johnson & Johnson (JNJ) stock dropped by 0.93% primarily due to investor actions, such as Manchester Financial Inc. reducing its holdings, mixed ratings and target price adjustments from several analysts, and a recent quarterly earnings report that, despite beating estimates, showed a decline in EPS compared to the same quarter last year. Johnson & Johnson (JNJ) stock fell by 0.93% despite receiving a "Moderate Buy" consensus rating from analysts due to mixed sentiments in recent evaluations, with half of the analysts maintaining a hold rating.
	2024-10-28	+0.45 %
Johnson & Johnson's (JNJ) stock rose by 0.45% due to increased investments in CVRx, Inc. by JNJ and other institutional investors, along with positive analysts' ratings on CVRx, indicating investor confidence in potential growth. Johnson & Johnson (JNJ) stock rose by 0.45% due to increased investments from institutional investors, such as GHP Investment Advisors Inc., and a positive earnings report that exceeded analysts’ expectations. Johnson & Johnson (JNJ) stock rose by 0.45%, attributed to increased investor confidence as Mirae Asset Global Investments significantly expanded its holdings, reflecting a trend of institutional investment growth and positive quarterly earnings results that exceeded analysts' expectations. Johnson & Johnson (JNJ) stock rose by 0.45%, likely driven by increased institutional investment, strong recent earnings that beat analyst expectations, and positive analyst ratings with raised price targets. Johnson & Johnson (JNJ) stock was up 0.45% last night likely due to increased investor confidence stemming from its recent acquisition of additional shares in CVRx, Inc., alongside positive ratings from several analysts, indicating strong market interest in the company's performance.
	2024-10-25	-1.7 %
Johnson & Johnson (JNJ) stock fell by 1.7% as Brighton Jones LLC reduced its holdings in the company by 7.9%, indicating potential investor concerns or a shift in market sentiment.
	2024-10-24	-1.32 %
Johnson & Johnson (JNJ) stock dropped 1.32% due to concerns over market conditions and potential impacts on the company's business performance. Johnson & Johnson (JNJ) stock fell by 1.32% after Accordant Advisory Group Inc significantly reduced its position in the company by 47.3%, indicating a potential lack of confidence in JNJ's future performance.
	2024-10-23	+1.47 %
Johnson & Johnson (JNJ) stock rose 1.47% after Waldron Private Wealth LLC increased its investment in the company, alongside significant interest from various institutional investors, indicative of positive sentiment towards the stock following strong quarterly earnings results that exceeded analysts' expectations. Johnson & Johnson (JNJ) stock rose 1.47% due to a combination of strong quarterly earnings that exceeded analyst expectations, several analysts raising their price targets on the stock, and maintaining a positive outlook with multiple buy ratings from equity research firms. Johnson & Johnson (JNJ) stock increased by 1.47% last night, likely due to significant investment activity from institutional investors, positive comments from brokerages raising price targets, and the company's recent strong earnings report that exceeded analyst expectations. The article discusses the rise of Johnson & Johnson's (JNJ) stock by 1.47% last night, which is likely attributed to increased investor confidence and buying activity, reflected in significant institutional investment activities and analysts’ favorable outlook for the company. Johnson & Johnson (JNJ) stock rose by 1.47% following RFP Financial Group LLC's significant increase of 56.9% in its holdings of the company's shares during the third quarter, indicating strong investor confidence and demand for the stock.
	2024-10-22	+0.38 %
Johnson & Johnson (JNJ) stock rose 0.38% following a successful earnings report that exceeded consensus estimates on both earnings per share and revenue, along with several institutional investors increasing their holdings in the company. The article highlights that Johnson & Johnson (JNJ) stock experienced a slight increase of 0.38%, and it likely rose due to positive market sentiment or specific developments related to the company, despite a previous report of a 0.1% decline. Johnson & Johnson (JNJ) stock rose by 0.38% due to increased institutional investment, strong quarterly earnings that exceeded analyst expectations, and favorable analyst ratings which contributed to positive investor sentiment. Johnson & Johnson (JNJ) stock rose by 0.38% likely due to positive earnings results exceeding analysts’ expectations, strong revenue growth, and a favorable outlook supported by increased institutional investment, despite a slight reduction in stakes from some investors. Johnson & Johnson (JNJ) stock rose by 0.38% following positive changes in institutional investments, analyst upgrades to price targets reflecting growing confidence in the company's earnings potential, and a recent quarterly earnings report that exceeded expectations.
	2024-10-21	-1.39 %
The article reports that Johnson & Johnson's stock (JNJ) fell by 1.39% following Claro Advisors LLC's significant reduction of its stake in the company by 93.3% during the third quarter. Johnson & Johnson (JNJ) stock fell by 1.39%, raising questions about whether it's time to sell. The decline could be attributed to market reactions, company-specific news, or broader economic factors impacting investor sentiment. Johnson & Johnson (JNJ) stock decreased by 1.39% amid a mixed performance in major U.S. equity indexes and growing concerns over the pace of interest rate cuts, which negatively affected sentiment in the broader market and particularly impacted sectors like real estate and health insurance. Johnson & Johnson (JNJ) stock fell by 1.39% due to investor sentiment being impacted by news regarding Kenvue, its spinoff company, as activist investor Starboard Value is taking a significant stake to address its underperformance, leading to concerns about JNJ's own valuation and outlook. Johnson & Johnson (JNJ) stock declined by 1.39% amid investor focus on Kenvue, its spun-off consumer health unit, which is facing pressure from activist investor Starboard Value to improve its stock performance after an 18% drop since its inception. The decline in JNJ stock can be attributed to the negative sentiment surrounding Kenvue, which may have raised concerns amongst investors about JNJ's ongoing financial health and the performance of its spun-off entities.
	2024-10-18	+0.4 %
Johnson & Johnson (JNJ) stock rose by 0.4% amidst ongoing competitive pressures from Eli Lilly, which has significantly increased in value, positioning itself as the most valuable pharmaceutical company. The stock's rise can be attributed to investor optimism and possibly market corrections following changes in the competitive landscape in the pharmaceutical sector. Johnson & Johnson (JNJ) stock increased by 0.4% last night, likely due to its strong overall market position and diversity within the S&P 500 index, as it remains part of a significant group of well-established companies that attract investor interest. Johnson & Johnson (JNJ) stock rose 0.4% last night, likely driven by Cardinal Capital Management increasing its stake in the company by 3.6% in the third quarter. Johnson & Johnson (JNJ) stock saw a slight increase of 0.4%, highlighting ongoing market fluctuations and investor sentiment. The rise in JNJ stock may be attributed to a combination of positive market trends, investor confidence, or company-specific announcements that boosted its appeal.
	2024-10-17	+0.12 %
The article discusses a recent court ruling in the case between Johnson & Johnson (J&J) and Auris Health Inc., wherein the court found J&J liable for over $1 billion in damages for breaching its contractual obligations regarding the development efforts of Auris's surgical robot, iPlatform, thereby impacting J&J's stock performance positively with a slight uptick of 0.12%. The increase in J&J's stock may be attributed to the market's reaction to the legal ruling and the ongoing restructuring efforts following the court's decision, which could suggest a potential for future growth or management optimizations in response to recent setbacks. Johnson & Johnson (JNJ) stock rose by 0.12% following LaFleur & Godfrey LLC's decision to increase its stake in the company by 2.5% during the third quarter, indicating investor confidence and positive sentiment towards JNJ. Johnson & Johnson's stock rose by 0.12% following the release of its Q3 results, which showed revenues and earnings exceeding estimates despite a slight cut in its earnings guidance; the increase can be attributed to better-than-expected sales in both its pharmaceuticals and medical devices segments, leading to an optimistic outlook for future sales growth. Johnson & Johnson's (JNJ) stock has experienced a 0.12% increase as it rebounds from previous setbacks related to the COVID-19 pandemic and the divestiture of Kenvue, with positive business growth anticipated moving forward. The stock goes up due to renewed investor confidence in the company's growth prospects after overcoming previous challenges.
	2024-10-16	+0.11 %
Johnson & Johnson's stock (JNJ) rose by 1.57% to $164.14, reflecting renewed investor confidence, likely due to strong performance metrics such as a solid dividend yield and a favorable price target. Johnson & Johnson (JNJ) stock experienced a slight increase of 0.11% attributed to its recent acquisition of a significant stake in Rapport Therapeutics, alongside interest from other institutional investors, suggesting a positive investor outlook and confidence in the company's growth potential in the biotechnology sector. The article discusses the recent 0.11% increase in Johnson & Johnson's (JNJ) stock, highlighting that such movements are often influenced by company performance, market conditions, and investor sentiment, although specific reasons for the increase were not detailed in the provided text. Johnson & Johnson (JNJ) stock rose by 0.11% following the announcement of Anil Kapur's appointment to the board of Nurix Therapeutics, as his extensive experience in successfully launching oncology drugs, including those developed by J&J, is perceived to positively influence Nurix’s future prospects in cancer treatment. The article discusses recent appointments at Goodbody Stockbrokers, including Paul Flynn as head of investment management, which aligns with the firm's growth strategy amidst a modestly improving financial outlook. Johnson & Johnson (JNJ) stock likely increased due to general market optimism or positive sentiment surrounding the company, but specific reasons for the stock's 0.11% rise are not detailed in the article.
	2024-10-15	+1.55 %
Johnson & Johnson (JNJ) stock rose 1.55% after the company reported better-than-expected third-quarter earnings and sales, driven by strong performance in its Innovative Medicine segment, particularly from cancer therapies, and raised its operational sales guidance for fiscal year 2024. Johnson & Johnson's stock rose 0.7% in premarket trading following the company's report of better-than-expected third-quarter sales and an increase in its full-year revenue guidance. The stock likely went up due to the positive earnings report and the upward revision of revenue expectations, suggesting strong financial performance and confidence in future growth. Johnson & Johnson (JNJ) stock rose by 1.55% amid a wider market decline influenced by corporate earnings reports and tensions in the Middle East, possibly due to a market perception of JNJ's stability or resilience relative to other sectors under scrutiny, despite overall disappointing earnings in the healthcare sector. Johnson & Johnson's stock has risen by 1.55%, largely due to a 5.2% increase in sales driven by strong performance in its pharmaceutical division and optimistic prospects for resolving ongoing talcum powder litigation, which may enhance investor confidence moving forward. Johnson & Johnson's stock rose 1.55% after the company exceeded third-quarter earnings expectations and slightly improved its full-year guidance.
	2024-10-14	+0.09 %
Johnson & Johnson's stock slightly increased by 0.09% amid a broader market rally where the S&P 500 and Dow Jones Industrial Average reached record highs, driven by strong corporate earnings and a positive sentiment despite ongoing geopolitical and election-related uncertainties. The increase in Johnson & Johnson’s stock price can be attributed to the anticipation of their upcoming earnings report, which, alongside other companies posting better-than-expected results, has boosted investor confidence. Johnson & Johnson (JNJ) stock rose 0.09% amid a generally positive outlook for U.S. markets leading into corporate earnings season, with optimism fueled by recent strong performances from major financial institutions and market anticipation surrounding upcoming earnings reports from JNJ and other companies. The increase in JNJ stock can be attributed to the overall buoyancy in Wall Street stocks, particularly in the financial sector, which reflects broader investor confidence and optimism as earnings season begins. Johnson & Johnson (JNJ) stock saw a slight increase of 0.09% as Wall Street anticipates a busy week of third-quarter earnings reports, including that of JNJ, amidst positive economic indicators such as a declining unemployment rate and consumer spending expectations for the holiday season. Johnson & Johnson (JNJ) stock rose 0.09% amidst a broader market rally characterized by all-time highs for major indices as investors responded positively to corporate earnings expectations and ongoing economic resilience, despite concerns related to upcoming elections and inflation risks. The increase in JNJ's stock price can be attributed to overall market momentum driven by strong corporate earnings results expected this earnings season, indicating healthy economic conditions that generally boost investor confidence. Johnson & Johnson (JNJ) stock rose 0.09% as part of a broader upward momentum in U.S. markets driven by investor optimism around corporate earnings and the hope that the Federal Reserve's interest rate cuts will support economic growth.
	2024-10-11	+0.59 %
Johnson & Johnson (JNJ) stock rose 0.59% in anticipation of strong third-quarter earnings, with analysts projecting a year-over-year increase in revenue and profits, driven by a recent $21 billion one-time gain from the spinoff of its consumer products division and ongoing acquisitions to expand its drug portfolio. Johnson & Johnson (JNJ) stock rose by 0.59% as the company is expected to report solid Q3 2024 results driven by strong sales from key pharmaceuticals like Darzalex, along with potential growth in the MedTech sector, despite facing some headwinds in certain markets like China. Johnson & Johnson's stock rose by 0.59% likely due to positive investor sentiment surrounding the ongoing trend of pharmaceutical companies, including Sanofi, divesting their consumer health divisions to focus on innovative therapies, signaling a commitment to growth and value creation in the biopharma sector. Johnson & Johnson (JNJ) stock experienced a 0.59% increase due to a favorable court ruling that allowed its subsidiary's bankruptcy cases related to talc products to remain in bankruptcy court, providing a clearer path to resolving these litigations. Johnson & Johnson (JNJ) stock rose by 0.59% despite Perpetual Ltd reducing its stake in the company by 11.8%, indicating potential investor confidence or market factors influencing the stock's performance.
	2024-10-10	-0.09 %
Johnson & Johnson (JNJ) stock was down by 0.09% as Brookstone Capital Management increased its holdings in the company, indicating mixed investor sentiment which might contribute to the slight decline in its stock price. Johnson & Johnson's stock (JNJ) experienced a slight decline of 0.09% following the reaffirmation of its "overweight" rating by Cantor Fitzgerald, which set a target price of $215.00, indicating that the drop may not be due to negative sentiment but rather market fluctuations. Johnson & Johnson (JNJ) stock went down by 0.09% amid a brewing proxy fight involving activist Starboard Value and Pfizer, as concerns about Pfizer's leadership and stock performance overshadowed sentiments in the broader pharmaceutical sector, contributing to a lack of investor confidence in pharmaceutical companies, including J&J.
	2024-10-09	+0.6 %
Johnson & Johnson's (JNJ) stock rose by 0.6% as institutional investors, including SL Advisors LLC and Wellington Management Group, increased their stakes in the company, indicating positive sentiment and confidence in JNJ's financial health and growth potential. Johnson & Johnson (JNJ) stock rose 0.6% due to a mix of institutional trading activity, positive earnings performance, and favorable analyst ratings, despite some target price adjustments. Johnson & Johnson (JNJ) stock rose by 0.6% due to Country Trust Bank increasing its holdings by 4.3%, indicating investor confidence in the company's performance. Johnson & Johnson (JNJ) stock rose by 0.6%, likely due to a combination of positive earnings performance, upgrades from analysts, and continued interest from institutional investors, with the company reporting strong quarterly earnings and maintaining a solid dividend yield. Johnson & Johnson's stock rose 0.3% after the Royal Bank of Canada increased its price target for the stock from $175.00 to $178.00, indicating a positive outlook.
	2024-10-08	+0.1 %
Johnson & Johnson (NYSE:JNJ) stock rose by 0.1% following an increase in its price target from $175.00 to $178.00 by Royal Bank of Canada, which affirmed an "outperform" rating on the stock. Johnson & Johnson (JNJ) stock was up 0.1% last night, likely due to the company's strong history of consistent dividend increases, which attracts dividend-focused investors amid declining inflation and an anticipated Fed rate-cut cycle. Johnson & Johnson (JNJ) stock rose by 0.1% after Mather Group LLC reduced its holdings by 5.3%, indicating potential adjustments in investor sentiment or market perception regarding the company. Johnson & Johnson (JNJ) stock experienced a marginal increase of 0.1%, closing at $159.44 after trading at lower points during the day, despite a significant drop in trading volume. The stock may have gone up due to a variety of factors, such as market sentiment, positive news related to the company, or broader market trends influencing investor behavior.
	2024-10-07	-0.47 %
Johnson & Johnson (JNJ) stock recently dropped by 0.47%, despite GAMMA Investing LLC increasing its stake in the company by 40.4% in the third quarter, indicating potential market pressures or investor sentiment affecting the stock's performance. The article discusses the appointment of Terry Kohler as Chief Financial Officer of Optinose, Inc., but notes that Johnson & Johnson (JNJ) stock fell by 0.47%. JNJ's decline could be attributed to various context-specific factors including market performance, investor sentiment, or sector-specific challenges, although the article does not provide specific reasons related to JNJ’s performance itself. Johnson & Johnson (JNJ) stock fell by 0.47% last night, likely due to ongoing concerns regarding litigation and regulatory challenges in the pharmaceutical and consumer health sectors. Johnson & Johnson's stock (JNJ) experienced a slight decline of 0.1% amid significantly lower trading volume, dropping to a price of $160.19. The stock may have gone down due to decreased trading activity and possibly investor concerns or market sentiment impacting its performance.
	2024-10-04	-0.13 %
The article discusses the current status of COVID-19 vaccines, particularly highlighting that Johnson & Johnson's COVID-19 vaccine is no longer available, which contributes to the company's stock decrease of -0.13%. The decline in the Johnson & Johnson (JNJ) stock is primarily due to the expiration of the government stock of its COVID-19 vaccine and the growing market dominance of newer mRNA vaccine options. Johnson & Johnson's stock (NYSE: JNJ) experienced a decline of 0.9% in Friday's trading, attributed to a significant drop in trading volume of 87% compared to its average session. Johnson & Johnson (JNJ) stock experienced a slight decline of 0.13%, primarily reflecting a consensus recommendation of "Hold" from analysts, indicating less bullish sentiment and uncertainty among brokerages about its future performance. Johnson & Johnson (JNJ) stock fell by 0.13% following a report that the Healthcare of Ontario Pension Plan Trust Fund significantly reduced its holdings in the company by 71.8% during the second quarter. Johnson & Johnson (JNJ) stock decreased by 0.13% last night, potentially due to broader market volatility and uncertainty surrounding the upcoming November 2024 presidential election, which could influence healthcare policies that directly affect pharmaceutical companies like JNJ.
	2024-10-03	-0.42 %
The Johnson & Johnson (JNJ) stock was down by 0.42%, reflecting broader market trends and possibly investor reactions to company news or macroeconomic factors affecting the healthcare sector. Johnson & Johnson (JNJ) stock fell by 0.42% due to concerns related to the pharmaceutical industry's advertising practices for COVID-19 vaccines, particularly in light of investigations revealing that major vaccine manufacturers, including Pfizer, exploited regulatory loopholes to avoid disclosing critical information about their vaccines in advertisements. Johnson & Johnson's stock (JNJ) fell 0.3% on Thursday, reaching a low of $160.27 and experiencing significantly reduced trading volume, which could indicate decreased investor interest or market concern. The stock's drop may be attributed to a variety of factors, including broader market trends, company-specific news, or investor sentiment impacting trading activity. The article discusses how Pfizer and other pharmaceutical companies effectively marketed their COVID-19 vaccines without adequate disclosures about their emergency use authorization status, raising ethical concerns. Johnson & Johnson (JNJ) stock fell by -0.42%, which could be attributed to overall market trends, investor sentiment regarding vaccine effectiveness, or specific concerns about the regulatory and legal scrutiny facing vaccine manufacturers, including JNJ. The article discusses the performance of various stocks across different sectors over the past three decades, highlighting that not all top performers are from the technology sector, while mentioning that Johnson & Johnson (JNJ) stock recently declined by 0.42%. The decline in JNJ's stock could be attributed to broader market trends affecting healthcare stocks or specific company news impacting investor sentiment.
	2024-10-02	-0.51 %
Johnson & Johnson (JNJ) stock fell by 0.51% after Creekside Partners revealed it had purchased a new position in the company, indicating a potential shift in investor sentiment or market reactions to new capital inflows. Johnson & Johnson (JNJ) shares experienced a slight decline of 0.2% during trading, reaching a low of $160.65, attributed to a significant drop in trading volume compared to average levels.
	2024-10-01	-0.04 %
The article discusses the appointment of Dr. Makoto Sugita as the new President and Chief Medical Officer at Nxera Pharma, which may have impacted investor sentiment towards Johnson & Johnson (JNJ), leading to a slight decline in its stock price by 0.04% as it could indicate a talent shift away from JNJ towards competitive biopharmaceutical firms. Johnson & Johnson (JNJ) stock experienced a slight decline of 0.04% due to various market factors, even as Truist Financial Corp increased its stake in the company by 4.9% in the second quarter. The decline in JNJ's stock price may be attributed to broader market trends, investor sentiment, or specific company news affecting stock performance. Johnson & Johnson (JNJ) shares experienced a slight decline of 0.04%, closing at $162.20 after a day of unusually low trading volume. The drop in stock price may be attributed to reduced trading activity, which often reflects investor hesitation or uncertainty. Johnson & Johnson's (JNJ) stock was down by 0.04% due to various market factors affecting investor sentiment, which might include economic indicators, industry competition, or company-specific concerns.
	2024-09-30	+0.41 %
Johnson & Johnson (JNJ) stock rose 0.41% despite Fiera Capital Corp reducing its position by 23.1% by selling nearly a million shares, indicating potential investor confidence or market factors that supported the rise. Johnson & Johnson (JNJ) stock increased by 0.41% due to its strong dividend sustainability, evidenced by a solid 3.07% yield and a manageable 72.70% payout ratio, coupled with the company's diverse healthcare portfolio that provides stability and growth potential. Johnson & Johnson (JNJ) stock rose 0.41% due to a general upward movement in the market, despite a significant drop in trading volume, with shares traded at $161.88. Johnson & Johnson's stock (JNJ) rose 0.41% following the restatement of its "overweight" rating and a price target of $215.00 set by Cantor Fitzgerald analysts, indicating positive investor sentiment and confidence in the company's future performance.
	2024-09-27	+0.01 %
Johnson & Johnson (JNJ) stock rose 0.83% following the release of promising results from two Phase 1b studies showing high overall response rates and significant effectiveness of their investigational treatments for relapsed or refractory multiple myeloma. Johnson & Johnson (JNJ) stock was up 0.01% likely due to its solid reputation for paying dividends and consistent growth, which makes it an attractive option for income investors looking for stable, long-term investments in large-cap stocks. Johnson & Johnson (JNJ) stock experienced a slight increase of 0.01% due to MBB Public Markets I LLC significantly enhancing its stake in the company by 1,827.5% during the second quarter.
	2024-09-26	+0.49 %
Johnson & Johnson (JNJ) stock increased by 0.49% due to strong Q2 2024 earnings driven by its pharmaceutical division, an attractive forward P/E ratio indicating undervaluation, and a strategic focus on higher-margin areas post the spinoff of its consumer health division. Johnson & Johnson (NYSE: JNJ) stock rose by 0.49% due to its strong financial performance, including a reported sales increase of 4.3% in Q2 2024 and successful regulatory approvals for new medications, which have attracted interest from hedge funds and indicate growth potential across its various segments. Johnson & Johnson (JNJ) stock rose by 0.49% following news that APG Asset Management US Inc. reduced its stake in the company by 8.7%, indicating potential shifts in investor sentiment or perceptions of the company's value.
	2024-09-25	-1.34 %
Johnson & Johnson (JNJ) stock declined by 1.34% likely due to market reactions to Sanofi’s announcement of its plans to spin off its consumer healthcare business, highlighting rising competition and strategic shifts in the pharmaceutical industry. Johnson & Johnson's stock (JNJ) fell by 1.34% to $160.98 amidst significantly lower trading volume, which was down 89% from its average session. The decrease in stock price can be attributed to factors such as market volatility, investor sentiment, or specific news related to the company or the overall market affecting trading activity. Johnson & Johnson (JNJ) stock fell by 1.34% amidst positive news for Masimo, a medical tech company, which saw its stock rise significantly following a leadership change. The decline in JNJ's stock may be attributed to investors' increased interest in Masimo's positive developments, shifting attention away from JNJ, or broader market trends affecting health-related stocks. Johnson & Johnson's (JNJ) stock fell by 1.34% following a 13.3% reduction in shares held by Insigneo Advisory Services LLC, indicating possible decreased investor confidence. Johnson & Johnson (JNJ) stock is down 1.34% amidst a strong overall stock market, likely due to ongoing market turbulence and investor sentiment shifting as it was not included among the top recommended stocks by influential analysts, despite its strong dividend history and financial health.
	2024-09-24	-0.27 %
Johnson & Johnson (JNJ) stock declined by 0.27% following a drop in trading volume, with only 890,099 shares changing hands compared to an average of 7,131,456 shares.
	2024-09-23	-0.57 %
Johnson & Johnson's (JNJ) stock fell 0.57% on Monday, trading at $163.36 with significantly reduced trading volume, likely indicating investor concern or market reaction affecting demand. The article discusses the importance of innovative leadership in adapting to disruptive changes but notes that Johnson & Johnson's (JNJ) stock fell by 0.57%, which could be attributed to broader market conditions or specific concerns related to the company, though these reasons are not detailed in the provided text.
	2024-09-20	-0.4 %
Johnson & Johnson's stock fell by 0.4% as the company increased its settlement offer from $6.5 billion to $8.2 billion to resolve thousands of lawsuits related to allegations that its baby powder caused cancer, indicating increased financial liability amid ongoing litigation. Johnson & Johnson (JNJ) stock declined by 0.4% despite the FDA approving its Rybrevant drug for advanced lung cancer, likely due to overall market volatility or profit-taking following the positive news rather than concerns about the approval itself.
	2024-09-17	+0.05 %
Johnson & Johnson's (JNJ) stock rose by 0.05% due to its strong performance in the pharmaceutical sector, particularly driven by new drug sales, a robust medical devices business, and higher profitability compared to Disney, despite facing some challenges with older drugs and competition.
	2024-09-16	+0.89 %
Johnson & Johnson (JNJ) stock rose by 0.89% following the release of encouraging data at the ESMO Conference regarding its TAR-200 treatment for bladder cancer, highlighting strong response rates and a focus on duration of response, which has attracted investor interest and reaffirmed optimism from Goldman Sachs.
	2024-09-13	+0.53 %
Johnson & Johnson (JNJ) stock rose by 0.53% following positive developments in the oncology drug development landscape, including collaborations with companies like Mersana Therapeutics, which are experiencing investor confidence and significant clinical trial advancements. Johnson & Johnson (JNJ) stock increased by 0.53% likely due to positive investor sentiment following major developments in Cidara Therapeutics, which include a strategic refocus, leadership changes, and upgrades from analysts that may influence the overall market perception and improve confidence in related sectors.
	2024-09-12	-0.11 %
Johnson & Johnson (JNJ) stock declined by 0.11% due to broader market conditions and investor sentiment affecting large-cap healthcare companies, alongside recent developments in related companies like Protagonist Therapeutics raising their price targets, which can shift focus away from JNJ. Johnson & Johnson (JNJ) stock dipped by 0.11% following the announcement of results from the Phase 2 SKIPPirr study, which focused on strategies to lessen infusion-related reactions with their drug Rybrevant, indicating potential concerns about the effectiveness or implications of the study findings. The article discusses the recent 0.11% decrease in Johnson & Johnson (JNJ) stock, triggered by Cidara Therapeutics' announcement of a significant workforce reduction and strategic refocus on its influenza product candidate, alongside challenges in its financial health and market performance.
	2024-09-10	+0.46 %
The article reports a 0.46% increase in Johnson & Johnson's stock, amid a significant surge in Oracle's shares that greatly enriched its co-founder Larry Ellison, positioning him as one of the world's wealthiest individuals. Johnson & Johnson's stock may have gone up as a result of broader market trends influenced by positive earnings reports of other companies like Oracle, which can improve overall investor sentiment and confidence in the market.
	2024-09-09	+1.36 %
Johnson & Johnson (JNJ) stock rose 1.36% likely due to recent trading activities by members of Congress, particularly the delayed disclosures involving trades in JNJ, which have sparked discussions about potential legislative changes regarding stock trading by lawmakers and their families, thus increasing investor interest. Johnson & Johnson (JNJ) stock rose by 1.36% due to its strong dividend history, reliable performance in the healthcare sector, and overall market trends favoring dividend-paying companies, which offer stability and income during economic fluctuations. Johnson & Johnson (JNJ) stock rose by 1.36% due to positive developments and ongoing research in treatments for acute severe ulcerative colitis, which may enhance the company's position in the biopharmaceutical market. Johnson & Johnson (JNJ) stock rose 1.36% as the company's strong market performance was bolstered by positive developments in the drug pipeline and strategic partnerships within the biotech sector, contributing to investor confidence.
	2024-09-06	-0.37 %
The article reports on US Supreme Court Justice Samuel Alito's financial disclosures and controversies surrounding his financial relationships, as well as his holdings, including shares in Johnson & Johnson (JNJ), which fell by 0.37%. The stock's decline could be attributed to ongoing scrutiny over the company's performance amid ethical concerns in the judiciary, particularly involving high-profile cases that may affect investor sentiment. The article discusses the dissatisfaction of Nike shareholders who are proposing measures related to corporate responsibility, such as climate change and labor rights, amid a history of rejected proposals, indicating limitations in shareholder activism's influence. Johnson & Johnson (JNJ) stock went down due to investors' growing concerns over corporate responsibility, reflected by similar sentiment toward Nike’s handling of sustainability and labor issues, impacting confidence in the company's governance.
	2024-09-05	-1.42 %
The article discusses the recent decline of Johnson & Johnson (JNJ) stock, which was down 1.42%, suggesting that mirroring Warren Buffett's investment choices can sometimes lead to mixed results. The decline in JNJ's stock could be attributed to a variety of market factors or investor sentiments, potentially including broader economic conditions or company-specific news that affects investor confidence.
	2024-09-04	+0.12 %
Johnson & Johnson (JNJ) stock rose by 0.12%, influenced by the overall positive movements in the market and associated growth in companies like Xtalpi, which reported significant sales growth and a lucrative partnership deal, signaling strong investment interest in sectors related to pharmaceuticals and AI-driven drug discovery. The Johnson & Johnson (JNJ) stock saw a slight increase of 0.12%, likely due to its association with Genmab A/S, as the biotech company's financial performance and strategic developments, including royalties from JNJ's products like Darzalex, influence investor sentiment positively. Johnson & Johnson's (JNJ) stock increased by 0.12%, driven by positive market sentiment surrounding innovations in healthcare, including the potential of GLP-1 drugs like Ozempic to treat various diseases and the company's partnerships in AI drug discovery.
	2024-09-03	+0.78 %
Johnson & Johnson (JNJ) stock rose by 0.78%, potentially due to ongoing regulatory discussions in Congress regarding stock trading by lawmakers, which may positively influence investor sentiment towards the company amidst increased transparency and potential changes in trading regulations.
	2024-08-30	+0.99 %
Johnson & Johnson (JNJ) stock rose by 0.99% due to a combination of positive investor sentiment, particularly regarding the performance of its partnership with Genmab A/S in the cancer treatment sector, and an overall market trend favoring equities despite challenges faced by short sellers. Johnson & Johnson (JNJ) stock rose by 0.99% last night, despite facing competition from rising healthcare stocks like DaVita and Duke Energy, due to the company's recent strong sales in pharmaceuticals and medical devices which may lead to potential future profit growth. The Johnson & Johnson (JNJ) stock rose by 0.99% likely due to positive market reactions following the publication of new research defining immune responses in allergic contact dermatitis, which may enhance JNJ's position in the dermatology and immunotherapy markets. Johnson & Johnson (JNJ) stock rose 0.99% likely due to positive developments in the vaccine sector, particularly the FDA's expanded approval for Emergent BioSolutions' smallpox vaccine, which may influence investor sentiment toward JNJ's vaccine-related business.

1
500 / page